Bartomeu M. S.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
Data & Insights
Has run more than one trial at 299 of 574 partner sites.
Specializations
Advanced NSCLC Research
The investigator specializes in treating advanced and metastatic non-small cell lung cancer, with particular focus on various therapeutic approaches including immunotherapy combinations and targeted treatments.
- Metastatic NSCLC management
- Combined therapy approaches
- Treatment resistance strategies
Targeted Therapeutics
Expertise in developing treatments for specific genetic mutations in lung cancer, including EGFR mutations, ALK-positive NSCLC, and KRAS G12C mutations. Focus on precision medicine approaches for various molecular subtypes.
- Biomarker-driven therapies
- Novel targeted agents
- Resistance mechanism studies
Surgical Oncology Integration
Investigation of neoadjuvant and adjuvant treatments in resectable lung cancer, combining surgical interventions with immunotherapy approaches. Special interest in improving outcomes for early-stage disease.
- Perioperative therapy optimization
- Early-stage NSCLC treatment
- Post-surgical therapeutic strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.